![](https://cdn.sanity.io/images/0vv8moc6/hcplive/af7ac55ee04ad4f7aee75c4f49e6a295e3ed0331-396x370.jpg?fit=crop&auto=format)
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort
Interim findings from the Phase 2 PRISM population extension cohort demonstrated the efficacy and tolerability of 4D-150 gene therapy for treating neovascular (wet) age-related macular degeneration (nAMD). These data, presented at the American Society of …